IRIS
CIARDIELLO, Fortunato
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.014
EU - Europa 10.820
AS - Asia 1.591
SA - Sud America 22
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 7
Totale 23.490
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.923
IE - Irlanda 3.515
UA - Ucraina 1.708
GB - Regno Unito 1.477
IT - Italia 1.184
DE - Germania 913
FR - Francia 570
CN - Cina 563
SG - Singapore 550
SE - Svezia 458
FI - Finlandia 451
GR - Grecia 350
TR - Turchia 285
CA - Canada 84
PK - Pakistan 46
VN - Vietnam 45
BE - Belgio 44
RU - Federazione Russa 36
PL - Polonia 28
CZ - Repubblica Ceca 26
KR - Corea 26
NL - Olanda 25
IN - India 21
EU - Europa 15
AU - Australia 13
JP - Giappone 12
ES - Italia 11
BR - Brasile 10
IR - Iran 10
IL - Israele 9
HK - Hong Kong 8
NZ - Nuova Zelanda 8
MX - Messico 6
AT - Austria 5
CH - Svizzera 4
CL - Cile 4
CO - Colombia 4
HU - Ungheria 4
MK - Macedonia 4
MY - Malesia 4
TW - Taiwan 4
GI - Gibilterra 2
ID - Indonesia 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
ZA - Sudafrica 2
AR - Argentina 1
BY - Bielorussia 1
CR - Costa Rica 1
EC - Ecuador 1
EG - Egitto 1
IQ - Iraq 1
LK - Sri Lanka 1
MA - Marocco 1
MN - Mongolia 1
NG - Nigeria 1
PH - Filippine 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SC - Seychelles 1
TN - Tunisia 1
Totale 23.490
Salva come PNG Salva come JPEG
Città #
Dublin 3.499
Jacksonville 2.638
Chandler 1.694
Wilmington 694
Princeton 560
Chicago 536
Medford 494
Falls Church 334
Boardman 310
Singapore 309
New York 303
San Mateo 293
Roxbury 260
Ann Arbor 250
Bremen 233
Caserta 191
Woodbridge 161
Beijing 139
Naples 137
Cambridge 125
Des Moines 118
Nanjing 92
Ashburn 78
Houston 65
Elora 59
Jinan 59
Napoli 55
Mountain View 52
Dong Ket 42
Norwalk 42
Brussels 39
Düsseldorf 39
Nanchang 33
Lappeenranta 28
Kraków 26
Los Angeles 26
Brno 23
Auburn Hills 22
Redwood City 21
Helsinki 20
Shenyang 20
Venice 20
Rome 19
Munich 17
Milan 16
Shanghai 16
Tianjin 16
Kunming 15
Aiello Del Sabato 14
Ottawa 14
Hebei 13
Redmond 12
Taiyuan 12
Amsterdam 11
Aversa 11
Fairfield 11
Lanzhou 11
Groningen 10
Haikou 10
Hangzhou 10
London 10
Orange 10
Zhengzhou 10
Islamabad 9
Seattle 9
Bahawalpur 8
Changsha 8
Frederick 8
Guangzhou 8
Hefei 8
Pozzuoli 8
Salerno 8
Taizhou 8
Battipaglia 7
Cava Dei Tirreni 7
Changchun 7
Florence 7
Madrid 7
Acerra 6
Castellammare Di Stabia 6
Giv‘atayim 6
Sennori 6
Somma Vesuviana 6
Boydton 5
Ercolano 5
Hasselt 5
Marigliano 5
Moscow 5
Ningbo 5
Vienna 5
Bogotá 4
Brisbane 4
Hanover 4
Liverpool 4
Lviv 4
Mainz 4
Monte Di Procida 4
Oxford 4
San Nicola la Strada 4
Simi Valley 4
Totale 14.629
Salva come PNG Salva come JPEG
Nome #
Epigenetic mechanisms underlying prostate cancer radioresistance 1.332
ONCOLOGIA MEDICA 145
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis 101
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 100
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 99
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. 92
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 89
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 89
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 85
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 85
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 83
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 82
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 79
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 79
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 76
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 76
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 74
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 73
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 72
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 71
Chronic inflammation and oxidative stress in human carcinogenesis 71
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 71
TRASTUZUMAB RESISTANCE IN BREAST CANCER 71
Clinical management of advanced gastric cancer: Role of new molecular drugs. 70
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 70
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 69
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 68
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 66
Farmacogenomica e cancro colorettale 66
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 65
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study) 64
AXL is an oncotarget in human colorectal cancer 64
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 63
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. 63
Treatment of gastric cancer. 63
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 63
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 62
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 62
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients 61
Antiangiogenic drugs in non small cell lung cancer treatment 61
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 61
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 61
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial 60
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 60
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 59
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 59
Chemoradiotherapy as adjuvant treatment of gastric cancer 59
Therapeutic integration of signal trasdution targeting agents an conventional anticancer treatments 59
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 59
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 59
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 59
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 58
Combination of anti-EGFR drugs and other molecular targeted agents as anti-cancer strategy 58
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 58
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 58
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 58
Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer 57
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 57
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 57
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model 56
Determination of molecular marker expression can predict clinical outcome in colon carcinomas 56
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status 56
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 56
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 56
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 56
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 55
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 55
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 55
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 55
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 55
Fatty acid composition and δ13 C of bulk and individual fatty acids as marker for authenticating Italian PDO/PGI extra virgin olive oils by means of isotopic ratio mass spectrometry. 54
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies 54
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 54
A meta-analysis on the interactionbetween HER-2 expression and response to endocrine treatment in advanced breastcancer 54
Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation 54
Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. 54
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer 54
A possible connective tissue primary lymphoepithelioma-like carcinoma (LELC). 54
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 54
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy 54
Vandetaninb, a dual inhibitor of VEGFR and EGFR tyrosine kinase activity 53
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC 53
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells 53
NM23 gene expression correlates with cell growth rate and S-phase 53
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 53
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 53
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase 53
ZD1839 (Iressa): preclinical studies and pharmacology 53
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 53
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? 53
Targeting EGFR in Pancreatic Cancer Treatment. 53
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 53
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 53
cooperativ antitumor effect of multitarget kinase inhibitor zd6474 and ionizing radiation in glioblastoma 52
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 52
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: A phase II study 52
Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 52
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 52
Metachronous Gastrointestinal Stromal Tumors (Gists) or relapse of the primary tumor ? A challenging case of multiple Gists in an elderly patient 52
Key cancer cell signal transduction pathways as therapeutic targets 51
Totale 7.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.962
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.962
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.960 544 490 72 61 448 48 556 148 307 139 100 47
2020/20213.781 395 39 440 166 577 42 542 414 69 504 429 164
2021/20224.210 405 171 289 158 1.311 74 83 116 160 167 301 975
2022/20237.076 799 176 392 603 676 569 31 367 3.147 44 137 135
2023/20242.904 246 91 130 249 1.003 337 61 61 48 27 199 452
2024/202584 84 0 0 0 0 0 0 0 0 0 0 0
Totale 24.336